Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
1546.68RON
În stoc
Număr Catalog 804-HY-13024CategorieAfaceri și industrie > Știință și laboratorFurnizorMedChemExpressGentaurDimensiune50mgTipsingle